Search

Displaying results 1151 - 1160 of 1786 in total
  1. Drug

    Drometrizole trisiloxane

    go.drugbank.com/drugs/DB11585
    Approved

    Despite being used elsewhere in the world with relatively few reports of adverse reactions, the FDA continues to cite that the existing scientific record is not sufficient to establish the compound as

  2. Drug

    Tivozanib

    go.drugbank.com/drugs/DB11800
    ApprovedInvestigational

    It was approved on March 10, 2021 by the FDA. Marketed by Aveo Oncology, tivozanib is a promising therapy for individuals with RCC who have not been treated successfully with other therapies.[L32524]

  3. Drug

    Sugammadex

    go.drugbank.com/drugs/DB06206
    ApprovedInvestigational

    Sugammadex (brand name Bridion) is marketed by Merck Sharp and Dohme, and was approved by the United States FDA on December 15, 2015.

  4. Drug

    Betahistine

    go.drugbank.com/drugs/DB06698
    ApprovedInvestigational

    [A220333,L16403] Betahistine was first approved by the FDA in the 1970s but withdrawn within approximately 5 years due to a lack of evidence supporting its efficacy.

    Products: Nra-betahistine
  5. Drug

    Ancestim

    go.drugbank.com/drugs/DB09103
    ApprovedWithdrawn

    It was submitted to the FDA under the status of recommendation for approval with a 10 to 1 votes.

  6. Drug

    Dotatate gallium Ga-68

    go.drugbank.com/drugs/DB13925
    ApprovedInvestigationalWithdrawn

    [A31358] Dotatate gallium 68 was developed by Advanced Accelerator Applications USA, Inc. and FDA approved in June 1, 2016.

  7. Drug

    Nonacog beta pegol

    go.drugbank.com/drugs/DB13933
    ApprovedInvestigational

    [A31496] Nonacog beta pegol was developed by Novo Nordisk and received its first global approval by the FDA on May 31, 2017,[L1098] followed by the European Commission approval on June 2, 2017.

  8. Drug

    Peanut oil

    go.drugbank.com/drugs/DB13964
    ApprovedWithdrawn

    [A33169] Under the FDA, peanut oil is categorized as an approved inactive ingredient for its use in drug products.

  9. Drug

    L-Acetylleucine

    go.drugbank.com/drugs/DB16956
    ApprovedInvestigational

    [A264439] In September 2024, the FDA approved levacetylleucine for the treatment of select patients with NPC.[L51444]

  10. Drug

    Lotilaner

    go.drugbank.com/drugs/DB17992
    ApprovedInvestigationalVet approved

    [A260741] On July 25, 2023, lotilaner was approved by the FDA for the treatment of Demodex blepharitis, making it the first and only approved therapeutic for this condition.[L47551]